Drugmaker tried to shred records before FDA inspection, agency claims

Alia Paavola - Print  | 

FDA inspectors claim that Strides Pharma Science, an India-based drugmaker that sells numerous drugs in the U.S., attempted to shred and dispose of quality-control records prior to an agency inspection, according to Bloomberg. 

Inspectors allegedly found discarded records in a 55-gallon drum in the company's scrapyard and discovered records awaiting shredding at one of Strides' manufacturing facilities.

The agency sent a warning letter to Strides CEO Arun Kumar detailing the violations. The letter, sent July 1, was made public July 16.

"The uncontrolled destruction of records, and your lack of adequate documentation practices, raise questions about the effectiveness of your [quality unit] and the integrity and accuracy of your records," the warning letter reads. 

Strides manufactures several medications, including ibuprofen and losartan, one of the drugs involved in a series of nationwide recalls over a potentially carcinogenic impurity. 

The warning letter also details other violations by Strides, including failing to adequately investigate an impurity found in an active ingredient used to make a drug. The FDA redacted the name of the drug in the warning letter. 

Access the full warning letter here.

More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation's 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.